Title: Evaluating the association of *APOE* genotype and cognitive resilience in SuperAgers

Authors: Alaina Durant, BS[a]; Shubhabrata Mukherjee, MS, PhD[b]; Michael L. Lee, MPH, PhD[b]; Seo-Eun Choi, PhD[b]; Phoebe Scollard, MA[b,c]; Brandon S. Klinedinst, PhD[b]; Emily H. Trittschuh, PhD[d,e]; Jesse Mez, MS, MD[f]; Lindsay A. Farrer, PhD[f,g,h]; Katherine A. Gifford, PsyD[a,h]; Carlos Cruchaga, PhD[i,j]; Jason Hassenstab, PhD[k]; Adam C. Naj, PhD[l,m]; Li-San Wang, PhD[m]; Sterling C. Johnson, PhD[n,o]; Corinne D. Engelman, MSPH, PhD[n,o]; Walter A. Kukull, PhD[p]; C. Dirk Keene, MD, PhD[q]; Andrew J. Saykin, PyD[r,s]; Michael L. Cuccaro, PhD[t]; Brian W. Kunkle, MPH, PhD[t]; Margaret A. Pericak-Vance, PhD[t]; Eden R. Martin, PhD[t]; David A. Bennett, MD[u]; Lisa L. Barnes, PhD[u]; Julie A. Schneider, MD[u]; William S. Bush, PhD[v]; Jonathan L. Haines, PhD[v]; Richard Mayeux, MD, MSc[w]; Badri N. Vardarajan, MS, PhD[w]; Marilyn S. Albert, PhD[x]; Paul M. Thompson, PhD[y]; Angela L. Jefferson, PhD[a,z]; The Alzheimer's Disease Neuroimaging Initiative (ADNI)*; Alzheimer's Disease Genetics Consortium (ADGC); The Alzheimer's Disease Sequencing Project (ADSP); Paul K. Crane, MD, MPH[b]; Logan Dumitrescu, MS, PhD[a,z,aa]; Derek B. Archer, PhD[a,z,aa]; Timothy J. Hohman, PhD[a,z,aa]; Leslie S. Gaynor, PhD[a,bb]

[a]Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA
[b]Department of Medicine, University of Washington, Seattle, WA, USA
[c]University Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR1219, Bordeaux, France
[d]Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA
[e]VA Puget Sound Health Care System, GRECC, Seattle, WA, USA
[f]Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
[g]Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
[h]Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
[i]Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA
[j]NeuroGenomics and Informatics Center, Washington University in St. Louis, St. Louis, MO, USA
[k]Department of Neurology and Department Psychological & Brain Sciences, Washington University in St Louis, St. Louis, MO, USA
[l]Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
[m]Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
[n]Alzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA
[o]Department of Population Health Sciences, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA
[p]Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
[q]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
[r]Department of Radiology and Imaging Services, Indiana University School of Medicine, Indianapolis, IN, USA

[s]Department of Medical and Molecular Genetics, School of Medicine, Indiana University, Indianapolis, IN, USA
[t]John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA
[u]Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA
[v]Cleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
[w]Department of Neurology, The Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center and The New York Presbyterian Hospital, New York, NY, USA
[x]Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
[y]Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
[z]Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA
[aa]Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
[bb]Division of Geriatric Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Funding Acknowledgement: The ADSP Phenotype Harmonization Consortium (ADSP-PHC) is funded by NIA (U24 AG074855, U01 AG068057 and R01 AG059716). This study was also funded by several additional funding sources, including K01 AG073584 (DBA) and K24 AG046373 (ALJ). The data contributed from the Adult Changes in Thought study was supported by NIA U19 AG066567. The data contributed from the Wisconsin Registry for Alzheimer's Prevention was supported by NIA R01 AG021155, R01 AG0271761, R01 AG037639, and R01 AG054047. Data collection and sharing for this project was funded (in part) by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIA U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Data contributed from MAP/ROS/MARS was supported by NIA R01 AG017917, P30 AG10161, P30 AG072975, R01 AG022018, R01 AG056405, UH2 NS100599, UH3 NS100599, R01 AG064233, R01 AG15819 and R01 AG067482, and the Illinois Department of Public Health (Alzheimer's Disease Research Fund). Data can be accessed at www.radc.rush.edu. The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar

Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI David Holtzman, MD), P30 AG066518 (PI Lisa Silbert, MD, MCR), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie A. Schneider, MD, MS), P30 AG072978 (PI Ann McKee, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Jessica Langbaum, PhD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Glenn Smith, PhD, ABPP), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P30 AG086401 (PI Erik Roberson, MD, PhD), P30 AG086404 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD). NACC data can be accessed at naccdata.org. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30 AG066444 (JCM), P01 AG03991 (JCM), and P01 AG026276 (JCM). The National Institute on Aging-AD Family Based Study (NIA-AD FBS; https://www.neurology.columbia.edu/research/research-centers-and-programs/national-institute-aging-alzheimers-disease-family-based-study-nia-ad-fbs) collected the samples used in this study and is supported by National Institute on Aging (NIA) grant U24 AG056270. Additional families were contributed to the NIA-AD FBS through NIH grants: R01 AG028786, R01 AG027944, R01 AG027944, RF1 AG054074, U01 AG052410. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. Data contributed from the Wisconsin Registry for Alzheimer's Prevention were supported by R01 AG027161.

Manuscript text word count: 2973

Abstract

"SuperAgers" are oldest-old adults (ages 80+) whose memory performance resembles that of adults in their 50s to mid-60s. Factors underlying their exemplary memory are underexplored in large, racially diverse cohorts. Thus, the objective of the present study is to determine the frequency of *APOE* genotypes in non-Hispanic Black and non-Hispanic White SuperAgers compared to middle-aged (ages 50-64), old (ages 65-79), and oldest-old (ages 80+) controls and Alzheimer's disease (AD) dementia cases. This multicohort study selected data from eight longitudinal cohort studies of normal aging and AD with variable recruitment criteria and follow-up intervals, including both population-based and clinical-based samples. Inclusion in our analyses required *APOE* genotype, that participants be age 50+, and are identified as either non-Hispanic Black or non-Hispanic White. In total, 18,080 participants were included in the present study with a total of 78,549 datapoints. Harmonized, longitudinal memory, executive function, and language scores were obtained from the Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC). SuperAgers, controls, and AD dementia cases were identified by cognitive scores and clinical diagnoses across multiple timepoints when available. SuperAgers were compared to AD dementia cases and cognitively normal controls using age-defined bins (middle-aged, old, oldest-old). We found that, across racialized groups, SuperAgers had significantly higher proportions of *APOE*-ε2 (non-Hispanic White: middle-aged cases: OR = 4.55, 95%CI[3.30, 6.27], $P_{FDR} < 0.001$; old cases: OR = 4.02, 95%CI[3.26, 4.96], $P_{FDR} < 0.001$; oldest-old cases: OR = 2.03, 95%CI[1.68, 2.44], $P_{FDR} < 0.001$; non-Hispanic Black: middle-aged cases: OR = 3.59, 95%CI[1.60, 8.06], $P_{FDR} = 0.005$; old cases: OR = 4.56, 95%CI[2.75, 7.55], $P_{FDR} < 0.001$; oldest-old cases: OR = 2.73, 95%CI[1.75, 4.25], $P_{FDR} < 0.001$) alleles and lower proportions of *APOE*-ε4 alleles (non-Hispanic White: middle-aged cases: OR = 0.18, 95%CI[0.15, 0.21], $P_{FDR} < 0.001$; old cases: OR = 0.09, 95%CI[0.08, 0.11], $P_{FDR} < 0.001$; oldest-old cases: OR = 0.32, 95%CI[0.27, 0.37], $P_{FDR} < 0.001$; non-Hispanic Black: middle-aged cases: OR = 0.12, 95%CI[0.07, 0.22], $P_{FDR} < 0.001$; old cases: OR = 0.12, 95%CI[0.08, 0.18], $P_{FDR} < 0.001$; oldest-old cases: OR = 0.39, 95%CI[0.27, 0.57], $P_{FDR} < 0.001$) compared to cases. Similar differences were observed between SuperAgers and middle-aged and old controls. Non-Hispanic White SuperAgers had significantly lower proportions of *APOE*-ε4 alleles and significantly higher proportions of *APOE*-ε2 alleles compared to all cases and controls, including oldest-old controls (*APOE*-ε2: OR = 1.28, 95%CI[1.03, 1.59], $P_{FDR} = 0.035$; *APOE*-ε4: OR = 0.81, 95%CI[0.67, 0.99], $P_{FDR} = 0.044$). In a smaller but substantial sample of non-Hispanic Black SuperAgers, we found that non-Hispanic Black SuperAgers had significantly lower proportions of *APOE*-ε4 alleles compared to cases and younger controls (middle-aged controls: OR = 0.48, 95%CI[0.33, 0.71], $P_{FDR} = 0.001$; old controls: 0.66, 95%CI[0.47, 0.94], $P_{FDR} = 0.035$), and significantly higher proportions of *APOE*-ε2 alleles compared only to cases. The difference in *APOE* allele frequency between SuperAgers and oldest-old controls did not rise to the level of significance (*APOE*-ε2: OR = 1.63, 95%CI[0.93, 2.85], $P_{FDR} = 0.115$; *APOE*-ε4: OR = 1.18, 95%CI[0.70, 1.98], $P_{FDR} = 0.564$). In conclusion, in the largest study to date, we demonstrated strong evidence that the frequency of *APOE*-ε4 and -ε2 alleles differ between SuperAgers and AD dementia cases and cognitively normal controls. Further research is needed with larger samples of non-Hispanic Black SuperAgers to determine the role of *APOE* in SuperAging and whether there are distinctions in mechanisms conferring resilience across race groups.

Introduction

"SuperAgers" is a term used to describe oldest-old (ages 80+) adults with episodic memory performance most closely resembling adults in their 50s to mid-60s.[1,2] Studies suggest that resilience to Alzheimer's disease (AD) pathological changes and neurodegeneration may explain SuperAgers' high memory scores.[3-6] Further research is needed to elucidate factors conferring resilience to AD-related brain changes and subsequent cognitive decline in SuperAgers. Moreover, research is needed to explore resiliency factors in non-Hispanic Black (NHB) SuperAgers, as this group is largely understudied.[7]

APOE-ε4 is the strongest genetic risk factor for late-onset AD.[8] The Northwestern SuperAging project reported lower *APOE*-ε4 allele frequency in SuperAgers (N = 10-12) compared to non-demented older adults.[2,9] In contrast, most studies report no differences in *APOE*-ε4 allele frequency between SuperAgers and oldest-old adults with typical memory performance, both groups having lower *APOE*-ε4 allele frequency compared to AD dementia cases.[4-6,10-12] Notably, these studies have small SuperAger samples (N = 25-64)[4-6,10-12] oftentimes drawn from the same cohort, thus limiting their generalizability and reliability. Further, these studies exclusively include NHW participants.[4-6,10-12] To our knowledge, only one study has been published characterizing NHB SuperAgers (N = 61) and did not find a significant difference in *APOE*-ε4 allele frequency between SuperAgers and same-age controls.[7] Even fewer studies have explored the relationship of *APOE*-ε2, the protective *APOE* allele, and SuperAger status,[11-13] likely due to the low minor allele frequency of *APOE*-ε2. Studies of *APOE*-ε2 allele frequency and superior memory in the oldest-old have not found a significant relationship[11-13]; however, questions of statistical power, generalizability, and reliability remain.

The present study aims to explore *APOE*-ε4 and -ε2 allele frequency in SuperAgers compared to AD dementia cases and controls in a large, harmonized multicohort dataset from the Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC). Using a residual approach to evaluate harmonized cognitive domains (e.g., memory, executive function, language), we classified NHW and NHB middle-aged, old, and oldest-old adults as cases, controls, or SuperAgers, and compared *APOE*-ε4 and -ε2 allele frequency of SuperAgers to cases and controls by age bin. Although prior literature suggests that there is not a relationship between optimal memory in oldest-old age and *APOE* genotype, this is likely due to a limitation of sample size. The ADSP-PHC has enabled us to complete, to our knowledge, the largest and most racially diverse study to date of *APOE* allele frequency and SuperAger status. We hypothesize that SuperAgers will possess a lower frequency of *APOE*-ε4 alleles and a higher frequency of *APOE*-ε2 alleles compared to both AD dementia cases and controls.

Methods

Study Population. The ADSP-PHC was assembled in 2021 to provide large-scale harmonization of ADSP cohorts, spanning markers of cognition, neuroimaging, fluid biomarkers, and neuropathology. Cohorts that are part of ADSP-PHC and were included in the present study are: Adult Changes in Thought (ACT),[14] Alzheimer's Disease Neuroimaging Initiative (ADNI),[15] Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD),[16] National Alzheimer's Coordinating Centers (NACC),[17] National Institute on Aging Alzheimer's Disease Family Based Study (NIA-AD FBS),[18] Religious Orders Study/Rush Memory and Aging Project/Minority Aging Research Study (ROS/MAP/MARS),[19,20,21] Knight Alzheimer's Disease Research Center (Knight ADRC),[22] and Wisconsin Registry for Alzheimer's Prevention (WRAP).[23]

Written informed consent was obtained from all participants in each cohort, and research was carried out with protocols approved by each site's institutional review board. These

secondary analyses were approved by the Vanderbilt University Medical Center institutional review board.

Cognitive Domain Scores. Each cohort used different neuropsychological assessment tools to measure cognition which may not be on the same scale. We derived co-calibrated and harmonized cognitive domain scores for four domains (i.e., memory, executive function, language, and visuospatial) using confirmatory factor analysis.[24] Consistent with previous definitions of SuperAgers, only memory, executive function, and language domains were used in present analyses.[1,2] To ensure inclusion of high-quality harmonization, cognitive domain scores with a standard error of measurement > 0.6 (estimated during the co-calibration and composite generation procedure) were excluded. Visit the data dictionary at https://vmacdata.org/adsp-phc/data/data-dictionary/cognition to explore the cognitive variables from each cohort that make up each cognitive domain.

For the purposes of this study, regression-based normative scores were created for for participant classification. Age, years of education, sex, and cohort were regressed on cognitive domain score at each available timepoint. Residuals were used to capture cognitive performance not explained by demographic variables or cohort differences. Separate models were used for NHW and NHB participants.

Participant Classification*.* Participants were grouped by race (self or study reported), clinical status, and age (**Figure 1A**). Age bins were decided based on the age-related criteria of SuperAgers (ages 80+) and the adults whose memory performance is compared to oldest-old adults to determine SuperAger status (ages 50-64).[25] Therefore, the age bins included middle-aged (ages 50-64), old (ages 65-79), and oldest-old (ages 80+) adults. Participant classification was determined separately for NHW and NHB adults. Given that longitudinal data were available for most participants, and some participants' ages spanned multiple age bins, participant classification was decided using a predetermined schema (**Figure 1B**).

Firstly, participants with a clinical diagnosis of AD dementia at least once were considered cases. Across all cohorts, a diagnosis of AD dementia followed standard published criteria (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, or NINCDS-ADRDA).[26-28] Given that the present study focused on dementia cases likely due to AD, participants with comorbid neurological disorders (e.g., stroke, traumatic brain injury with significant loss of consciousness) or non-AD dementia (e.g., Dementia with Lewy Bodies, Vascular Dementia) diagnosed at any timepoint were excluded. Age bin was determined based on age at first AD dementia diagnosis.

Next, SuperAgers were identified using previously published criteria.[1,2] Across all cohorts, SuperAgers were defined as oldest-old adults with (1) memory score at or above the mean of middle-aged adults (ages 50-64), (2) executive function and language residual scores no more than 1 standard deviation below their same-aged peers (ages 80+) at the same visit as their superior memory performance, and (3) whose diagnosis remained "cognitively normal" for the duration of study participation.

Regarding classification as a control, given the importance of oldest-old (ages 80+) participants to our central analyses, we sequentially identified oldest-old, middle-aged, and then old controls. Criteria for controls included (1) memory, executive function, and language residual scores no lower than 1 standard deviation below their same-aged peers at a single visit, and (2) whose diagnosis remained "cognitively normal" for the duration of their study participation.

***APOE* Genotyping.** *APOE* haplotypes were determined from the single nucleotide variants rs7412 and rs429358 for ACT, BIOCARD, NACC, NIA-AD FBS, Knight ADRC, and

WRAP and from pyrosequencing of *APOE* codons 112 and 158 for ADNI and ROS/MAP/MARS.[29,30]

Statistical Analyses. Statistical analyses were performed using R Statistical Software (v4.2.3.).[31] Logistic regression models examined differences in *APOE*-ε4 and -ε2 allele frequency of SuperAgers compared to cases and controls at all age bins. *APOE* allele positivity was determined by allele presence (0 = no allele present, 1 = one or more alleles present). Models covaried for sex and years of education due to their known modifying effects on the relationship of *APOE* and late-life cognition.[32,33] Sensitivity analyses included analyses removing individuals with *APOE*-ε2/ε4 genotype, adding *APOE* genotyping method as a covariate, and removing individuals with data from only a single timepoint. Additionally, to address concerns regarding differences in sample size between the NHW and NHB samples, we included sensitivity analyses randomly down-sampling the NHW sample by participant classification and cohort. Correction for multiple comparisons was applied using Benjamini-Hochberg false discovery rate (FDR) procedure.[34] Results tables include odds ratios (OR), confidence intervals (CI), and FDR-corrected *p*-values.

Results

Participant Characteristics. In total, 18,080 participants were included in the present analyses with a total of 78,549 datapoints (**Table 1**). Participants completed an average of 4 ± 4 visits over 5 ± 5 years. The number of follow-up visits and length of follow-up varied by cohort due to differences in study design; for example, while participants from BIOCARD completed an average of 9 ± 3 visits over 13 ± 4 years, participants from NIA-AD FBS completed an average of 1 ± 1 visits over 2 ± 3 years.

Average baseline age varied by cohort ($\text{Age}_{[\text{all cohorts}]}$ = 72 ± 10); the youngest cohorts on average, BIOCARD and WRAP, primarily recruited cognitively normal participants. Generally, cohorts were highly educated ($\text{Years of Education}_{[\text{all cohorts}]}$ = 15 ± 3), mostly female (62.9%), and mostly NHW (85.4%). The proportion of each *APOE* genotype differed by cohort, with higher proportions of ε3/ε4 and ε4/ε4 genotypes in cohorts with a higher proportion of AD dementia cases.

Participant Classification. SuperAgers made up 9% of all participants (N = 1,623). The two youngest cohorts, BIOCARD and WRAP, did not contribute any SuperAgers. Cognitively unimpaired controls comprised 42% of all participants (N = 7,628), and cases made up 49% of all participants (N = 8,829).

Table 2 displays participant characteristics of NHW and NHB SuperAgers, controls, and cases in age-defined bins. On average, NHW SuperAgers (N = 1,412) were somewhat older, had more years of education, and included more males than NHB SuperAgers (N = 211). There was not a difference in the proportion of participants in each participant classification (SuperAger, control, case) across racialized groups ($\chi^2_{[2]}$ = 3.79, p = 0.15). Comparing NHW and NHB participants across age-defined bins, all NHW bins had greater average years of education and a higher proportion of males than NHB bins.

***APOE* Allele Frequency.** In NHW comparisons (**Table 3A**), SuperAgers had a significantly higher frequency of *APOE*-ε2 alleles (**Figure 2A;** middle-aged controls: OR = 1.38, 95%CI[1.13, 1.68], P_{FDR} = 0.002; old controls: OR = 1.24, 95%CI[1.05, 1.47], P_{FDR} = 0.015; oldest-old controls: OR = 1.28, 95%CI[1.03, 1.59], P_{FDR} = 0.035; middle-aged cases: OR = 4.55, 95%CI[3.30, 6.27], P_{FDR} < 0.001; old cases: OR = 4.02, 95%CI[3.26, 4.96], P_{FDR} < 0.001; oldest-old cases: OR = 2.03, 95%CI[1.68, 2.44], P_{FDR} < 0.001) and a significantly lower frequency of *APOE*-ε4 alleles (**Figure 2B**; middle-aged controls: OR = 0.37, 95%CI[0.31, 0.43], P_{FDR} < 0.001; old controls: OR = 0.55, 95%CI[0.47, 0.64], P_{FDR} < 0.001; oldest-old controls: OR = 0.81,

95%CI[0.67, 0.99], P_{FDR} = 0.044; middle-aged cases: OR = 0.18, 95%CI[0.15, 0.21], P_{FDR} < 0.001; old cases: OR = 0.09, 95%CI[0.08, 0.11], P_{FDR} < 0.001; oldest-old cases: OR = 0.32, 95%CI[0.27,0.37], P_{FDR} < 0.001) compared to all cases and controls. In contrast, NHB SuperAgers (**Table 3B**) had a significantly higher frequency of *APOE*-ε2 alleles only compared to cases (**Figure 2C;** middle-aged cases: OR = 3.59, 95%CI[1.60, 8.06], P_{FDR} = 0.005; old cases: OR = 4.56, 95%CI[2.75, 7.55], P_{FDR} < 0.001; oldest-old cases: OR = 2.73, 95%CI[1.75, 4.25], P_{FDR} < 0.001), and a significantly lower frequency of *APOE*-ε4 alleles compared to all cases and controls except oldest-old controls (**Figure 2D;** middle-aged controls: OR = 0.48, 95%CI[0.33, 0.71], P_{FDR} = 0.001; old controls: OR = 0.66, 95%CI[0.47, 0.94], P_{FDR} = 0.035; middle-aged cases: OR = 0.12, 95%CI[0.07, 0.22], P_{FDR} < 0.001; old cases: OR = 0.12, 95%CI[0.08, 0.18], P_{FDR} < 0.001; oldest-old cases: OR = 0.39, 95%CI[0.27, 0.57], P_{FDR} < 0.001).

Sensitivity Analyses. Analyses were repeated removing individuals with an *APOE*-ε2/ε4 genotype. Given their low frequency, very few participants were removed (**Supplementary Table 1;** NHW SuperAgers: N = 1,393; NHB SuperAgers: N = 200) and findings were preserved (**Supplementary Table 2**).

When *APOE* genotyping method was included as a covariate, findings were preserved (**Supplementary Table 3**).

Analyses were also repeated including only individuals with longitudinal data. Across racialized groups, SuperAgers' sample size was more substantially reduced (**Supplementary Table 4;** NHW SuperAgers: N = 1,053; NHB SuperAgers: N = 160). Findings were relatively similar, although differences in *APOE*-ε2 and -ε4 allele frequency between NHW SuperAgers and oldest-old controls were no longer significant (**Supplementary Table 5**).

To demonstrate the impact of sample size on the significance of NHB comparisons, we randomly down-sampled the NHW sample by participant classification and cohort (**Supplementary Table 6**). Differences in *APOE*-ε2 and -ε4 allele frequency between NHW SuperAgers and controls were no longer significant, except for the comparison between NHW SuperAgers and middle-aged controls (**Supplementary Table 7**).

Discussion

Mechanisms conferring resilience to memory decline in oldest-old age are yet unknown. This is the largest study to date of *APOE*-ε4 and -ε2 allele frequency in both NHW and NHB SuperAgers. Across 8 national aging cohorts, we identified 1,623 NHW and NHB SuperAgers with *APOE* genotyping using longitudinal harmonized cognitive and clinical data. As expected, we found that SuperAgers had a higher proportion of *APOE*-ε2 alleles and a lower proportion of *APOE*-ε4 alleles compared to individuals with AD dementia. Unlike previous studies of *APOE* genotype in NHW SuperAgers, we found significant differences in *APOE* genotype compared to controls of all ages, including oldest-old controls. Specifically, the odds of having ≥1 ε4 allele was about 20% lower in SuperAgers compared to same-age controls, and the odds of having ≥1 ε2 allele was about 30% higher in SuperAgers compared to same-age controls. This finding held when ε2/ε4 carriers were removed from analyses. Although NHB SuperAgers also had a greater frequency of *APOE*-ε2 alleles and a lower frequency of *APOE*-ε4 alleles compared to oldest-old controls, comparisons did not rise to the level of significance.

APOE-ε4 is the strongest genetic risk factor for late-onset AD,[8] and has been shown to be related to increased entorhinal and hippocampal atrophy[35] and amnestic cognitive impairment.[36,37] Our data are supportive of these findings, such that AD dementia cases had a greater proportion of *APOE*-ε4 alleles compared to controls.[38] Unlike most studies of genetic resilience in SuperAgers, we found that NHW SuperAgers had a lower proportion of *APOE*-ε4 alleles compared to oldest-old adults with typical memory performance. This was found in one

previous study published by Rogalski and colleagues,[2] but was not replicated by subsequent studies with larger samples of SuperAgers.[4-6,10-12] This finding is relatively unexpected. Across racialized groups, the effect of *APOE*-ε4 is most impressive prior to age 70.[39,40] Additionally, *APOE*-ε4 carriership is related to increased mortality.[41,42] In line with these studies, we found lower *APOE*-ε4 allele frequency in oldest-old compared to middle-aged and old controls. Despite NHW oldest-old controls being older than NHW SuperAgers on average, we found that SuperAgers had a significantly lower frequency of *APOE*-ε4 alleles compared to oldest-old controls, indicating that *APOE*-ε4 allele carriership influences memory even in adults who live past age 80. Moreover, dementia incidence increases exponentially with age,[43] suggesting that the oldest-old control group also represents exceptional aging. Despite this fact, our study found that NHW SuperAgers had a significantly lower frequency of *APOE*-ε4 alleles and a higher frequency of *APOE*-ε2 alleles compared to same-age peers, thus underscoring the utility of the SuperAgers phenotype for uncovering factors conferring resilience in cognitive aging.

The protective *APOE*-ε2 allele is related to lower likelihood of late-onset AD dementia[13,44] and better cognitive performance in older adults even in the presence of AD neuropathology.[45] Unlike *APOE*-ε4, *APOE*-ε2 carriership was previously shown to affect cognition after age 80; more precisely, although oldest-old *APOE*-ε2 carriers were as likely as *APOE*-ε4 carriers to meet neuropathologic criteria for AD, they were less likely to be diagnosed with dementia.[44] Despite this, no previous studies have found a relationship of *APOE*-ε2 allele frequency and SuperAger status.[11-13] The present study is the first to find that NHW SuperAgers had a significantly higher frequency of *APOE*-ε2 alleles compared to controls. Our results suggest that *APOE*-ε2 not only reduces the likelihood of dementia in oldest age but increases the likelihood one will possess optimal memory in oldest age. Future studies are needed to determine whether SuperAgers have similar levels of AD neuropathology compared to AD dementia cases as was previously found in oldest-old *APOE*-ε2 carriers without dementia.[44]

Genetic factors underlying the superior memory performance of NHB SuperAgers, a critically under-diagnosed and understudied group, are relatively unknown.[7] Previous research suggests that, while NHB individuals have higher proportions of *APOE*-ε4 alleles compared to NHW individuals, *APOE*-ε4 carriership is associated with attenuated risk for late-onset AD, yet similar mortality risk, in NHB individuals compared to NHW individuals.[40,46-48] The effect is likely related to global population ancestry; more specifically, *APOE*-ε4 carriership is associated with a greater risk of AD in NHB older adults with decreased global African ancestry or increased global European ancestry.[40] Similar to *APOE*-ε4, NHB individuals have higher proportions of *APOE*-ε2 alleles compared to NHW individuals.[46] Unlike *APOE*-ε4, researchers did not detect differences in the protective effect of *APOE*-ε2 alleles related to global population ancestry.[40] In fact, a recent study from the MARS cohort found that NHB older adults (ages 65+) with more *APOE*-ε2 alleles had slower cognitive decline over a 10-year study period.[49] Additionally, *APOE*-ε2 carriership was related to better survival in a sample of NHB and NHW individuals from NACC with and without AD neuropathology.[50] In the present study, NHB SuperAgers had significantly lower proportions of *APOE*-ε4 alleles compared to cases and younger controls, and significantly higher proportions of *APOE*-ε2 alleles compared only to cases. The lack of significant difference in *APOE* allele carriership between NHB SuperAgers and oldest-old controls may be explained by survivorship bias; recent research indicates that NHB adults have higher probability of survival from ages 70 and 80 to 100 compared to NHW adults.[51] NHB SuperAgers and cognitively normal oldest-old adults may share environmental and genetic factors, including *APOE*-ε2 allele carriership, that support survival and reduced mortality risk in older age, resulting in a lack of significant difference in *APOE* genotype between these two, very

similar groups. Importantly, the present study included a substantially smaller sample of NHB SuperAgers compared to NHW SuperAgers, although the sample was still far larger than has been previously reported.[7] Still, more research and targeted recruitment of high-performing NHB oldest-old adults is necessary to determine the role of *APOE* genotype in their sustained optimal memory performance.

Strengths and Limitations. The present study has several strengths, including being the largest and most racially diverse of its kind to explore the relationship of *APOE* genotype and optimal memory performance in both NHW and NHB SuperAgers. Our study also has several limitations. Firstly, the smaller sample size of NHB SuperAgers compared to NHW SuperAgers makes it difficult to interpret differences in odds ratios, which are biased and tend to be larger in smaller samples,[52] and statistical significance of the relationship of *APOE* allele frequency and SuperAger status across racialized groups. As mentioned previously, targeted recruitment of NHB SuperAgers is required to clarify the contribution of genetics to the superior memory performance of NHB adults in old age. Across cohorts, participants are highly educated, limiting generalizability to lower-educated or socioeconomically diverse populations. Additionally, studies have identified other genetic factors that may confer greater AD risk in NHB older adults compared to *APOE*, including *ABCA7*.[53,54] Future studies will need to consider other genetic factors that may be more relevant to exceptional aging in NHB older adults. Moreover, differences in the effect of genetic factors on AD risk have been associated with genetic ancestry.[40] Subsequent research leveraging advanced genetic analyses to consider admixture may further our understanding of genetic profiles underlying AD risk.

The present study uses the SuperAgers phenotype previously defined by Harrison and colleagues and replicated in both US- and non-US based studies.[1-3,6,9,11,12] The SuperAgers phenotype typically uses cross-sectional data to identify oldest-old adults with optimal memory performance. However, in participants with longitudinal data, we used more rigorous criteria, requiring that cognitively normal controls and SuperAgers did not receive a diagnosis of mild cognitive impairment, dementia, or other neurological disorders at any visit. A more recent study investigated the difference between older adults (ages 75+) that maintain optimal memory performance over time and those who do not and found that maintenance of optimal memory performance related to lower levels of AD pathology at baseline.[4] While most participants in the present study had longitudinal data indicating maintenance of SuperAger status over time, some participants only had cross-sectional data. Supplementary analyses revealed that, in a subset of participants in which we removed participants with only one timepoint of data, SuperAgers continued to display a higher proportion of *APOE*-ε2 alleles and a lower proportion of *APOE*-ε4 alleles compared to individuals with AD dementia and younger controls. While differences in *APOE* genotype between SuperAgers and oldest-old controls were not present in these sensitivity analyses, only 1,053 NHW SuperAgers and 160 NHB SuperAgers were included in these analyses, likely affecting our ability to detect significance in this subtle but striking comparison. There is an ongoing initiative that intends to answer complex questions about brain aging, resilience, and resistance in a well-characterized SuperAging cohort through longitudinal, multimodal data collection.[55,56] This research will contribute tremendously to our understanding of factors conferring resilience in oldest-old age.

Conclusions. We have limited knowledge of the genetic factors that contribute to optimal memory performance in oldest-old age. This is the largest and most racially diverse study to date to identify differences in *APOE*-ε4 allele frequency based on SuperAger status, and the first study of SuperAgers to find a relationship between *APOE*-ε2 allele frequency and SuperAger status. The present study reveals important information about potential differences in

the genetic factors associated with exceptional memory in oldest-old adults, a group at the highest risk for AD neuropathologic accumulation and dementia. While significant findings were restricted to NHW comparisons, study results importantly direct our attention to the need for targeted recruitment of high-performing NHB oldest-old adults to more definitively determine the role of genetics in sustained optimal memory performance across racialized groups.

References

1 Harrison, T. M., Mesulam, M. M., Rogalski, E. & Weintraub, S. Superior Memory and Higher Cortical Volumes in Unusually Successful Cognitive Aging. *Journal of the International Neuropsychological Society* **18**, 1081-1085 (2012). https://doi.org/10.1017/S1355617712000847
2 Rogalski, E. J. *et al.* Youthful Memory Capacity in Old Brains: Anatomic and Genetic Clues from the Northwestern SuperAging Project. *Journal of Cognitive Neuroscience* **25**, 29-36 (2013). https://doi.org/10.1162/jocn_a_00300
3 de Godoy, L. L. *et al.* Understanding brain resilience in superagers: a systematic review. *Neuroradiology* **63**, 663-683 (2021). https://doi.org/10.1007/s00234-020-02562-1
4 Dekhtyar, M. *et al.* Neuroimaging markers associated with maintenance of optimal memory performance in late-life. *Neuropsychologia* **100**, 164-170 (2017). https://doi.org/10.1016/j.neuropsychologia.2017.04.037
5 Gefen, T. *et al.* Morphometric and histologic substrates of cingulate integrity in elders with exceptional memory capacity. *Journal of Neuroscience* **35**, 1781-1791 (2015). https://doi.org/10.1523/JNEUROSCI.2998-14.2015
6 Harrison, T. M., Maass, A., Baker, S. L. & Jagust, W. J. Brain morphology, cognition, and β-amyloid in older adults with superior memory performance. *Neurobiology of aging* **67**, 162-170 (2018). https://doi.org/10.1016/j.neurobiolaging.2018.03.024
7 Trammell, A. R., Goldstein, F. C., Parker, M. W. & Hajjar, I. M. Characterization of African-American Super-Agers in the National Alzheimer's Coordinating Center cohort. *J Am Geriatr Soc* **72**, 1995-2005 (2024). https://doi.org/10.1111/jgs.18882
8 Corder, E. H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-923 (1993). https://doi.org/10.1126/science.8346443
9 Rogalski, E. *et al.* Cognitive trajectories and spectrum of neuropathology in SuperAgers: The first 10 cases. *Hippocampus* **29**, 458-467 (2019). https://doi.org/10.1002/hipo.22828
10 Mapstone, M. *et al.* What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. *Neurobiology of aging* **51**, 148-155 (2017). https://doi.org/10.1016/j.neurobiolaging.2016.11.007
11 Spencer, B. E. *et al.* Alzheimer's polygenic hazard score in SuperAgers: SuperGenes or SuperResilience? *Alzheimer's & Dementia: Translational Research & Clinical Interventions* **8**, e12321 (2022). https://doi.org/10.1002/trc2.1232
12 Garo-Pascual, M. *et al.* Brain structure and phenotypic profile of superagers compared with age-matched older adults: a longitudinal analysis from the Vallecas Project. *Lancet Healthy Longev* **4**, e374-e385 (2023). https://doi.org/10.1016/S2666-7568(23)00079-X
13 Corder, E. *et al.* Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nature genetics* **7**, 180-184 (1994). https://doi.org/10.1038/ng0694-180
14 Kukull, W. A. *et al.* Dementia and Alzheimer disease incidence: a prospective cohort study. *Archives of neurology* **59**, 1737-1746 (2002). https://doi.org/10.1001/archneur.59.11.1737
15 Jack Jr, C. R. *et al.* The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine* **27**, 685-691 (2008). https://doi.org/10.1002/jmri.21049
16 Sacktor, N. *et al.* The BIOCARD Index: A Summary Measure to Predict Onset of Mild Cognitive Impairment. *Alzheimer Disease & Associated Disorders* **31**, 114-119 (2017). https://doi.org/10.1097/WAD.0000000000000194
17 Beekly, D. L. *et al.* The National Alzheimer's coordinating center (NACC) database: an Alzheimer disease database. *Alzheimer Disease & Associated Disorders* **18**, 270-277 (2004). https://doi.org/lww/alz/88441/03-070R

18 Lee, J. H. *et al.* Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: Implication of Additional Loci. *Archives of neurology* **65**, 1518-1526 (2008). https://doi.org/10.1001/archneur.65.11.1518
19 Bennett, D. A. *et al.* Religious orders study and rush memory and aging project. *Journal of Alzheimer's disease* **64**, S161-S189 (2018). https://doi.org/10.3233/JAD-179939
20 Bennett, D. A. *et al.* Overview and findings from the Rush Memory and Aging Project. *Current Alzheimer research* **9**, 646-663 (2012). https://doi.org/10.2174/156720512801322663
21 Barnes, L. L., Shah, R. C., Aggarwal, N. T., Bennett, D. A. & Schneider, J. A. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. *Current Alzheimer research* **9**, 734-745 (2012). https://doi.org/10.2174/156720512801322627
22 Fernandez, M. V. *et al.* Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center. *Sci Data* **11**, 768 (2024). https://doi.org/10.1038/s41597-024-03485-9
23 Johnson, S. C. *et al.* The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. *Alzheimer's & dementia (Amsterdam, Netherlands)* **10**, 130-142 (2018). https://doi.org/10.1016/j.dadm.2017.11.007
24 Mukherjee, S. *et al.* Cognitive domain harmonization and cocalibration in studies of older adults. *Neuropsychology* **37**, 409 (2023). https://doi.org/10.1037/neu0000835
25 Harrison, T. M., Weintraub, S., Mesulam, M. M. & Rogalski, E. Superior Memory and Higher Cortical Volumes in Unusually Successful Cognitive Aging. *Journal of the International Neuropsychological Society* **18**, 1081-1085 (2012). https://doi.org/10.1017/S1355617712000847
26 McKhann, G. *et al.* Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-944 (1984). https://doi.org/10.1016/j.jalz.2011.03.005
27 McKhann, G. M. *et al.* The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers & Dementia: The Journal of the Alzheimer’s Association* **7**, 263-269 (2011). https://doi.org/10.1016/j.jalz.2011.03.005
28 Dubois, B. *et al.* Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *The Lancet Neurology* **6**, 734-746 (2007). https://doi.org/10.1016/S1474-4422(07)70178-3
29 Yu, L. *et al.* Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline. *Alzheimer's & Dementia* **13**, 1380-1388 (2017). https://doi.org/10.1016/j.jalz.2017.05.002
30 Naj, A. C. *et al.* Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature Genetics* **43**, 436-441 (2011). https://doi.org/10.1038/ng.801
31 R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria, 2021).
32 Lee, M. *et al.* Education and Cardiovascular Health as Effect Modifiers of APOE ε4 on Dementia: The Atherosclerosis Risk in Communities Study. *Journals of Gerontology Series A, Biological Sciences & Medical Sciences* **77**, 1199-1207 (2022). https://doi.org/10.1093/gerona/glab299
33 Hohman, T. J. *et al.* Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. *JAMA neurology* **75**, 989-998 (2018). https://doi.org/10.1001/jamaneurol.2018.0821
34 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)* **57**, 289-300 (1995). https://doi.org/10.1111/j.2517-6161.1995.tb02031.x

35 Juottonen, K., Lehtovirta, M., Helisalmi, S., Riekkinen, P. J., Sr. & Soininen, H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E ε4 allele. *J Neurology, Neurosurgy, and Psychiatry* **65**, 322-327 (1998). https://doi.org/10.1136/jnnp.65.3.322
36 Snowden, J. S. *et al.* Cognitive phenotypes in Alzheimer's disease and genetic risk. *Cortex; a journal devoted to the study of the nervous system and behavior* **43**, 835-845 (2007). https://doi.org/10.1016/s0010-9452(08)70683-x
37 Mukherjee, S. *et al.* Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. *Molecular Psychiatry* **25**, 2942-2951 (2018). https://doi.org/10.1038/s41380-018-0298-8
38 Poirier, J. *et al.* Apolipoprotein E polymorphism and Alzheimer's disease. *The Lancet* **342**, 697-699 (1993). https://doi.org/10.1016/0140-6736(93)91705-q
39 Farrer, L. A. *et al.* Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama* **278**, 1349-1356 (1997). https://doi.org/10.1001/jama.1997.03550160069041
40 Belloy, M. E. *et al.* APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. *JAMA neurology* **80**, 1284-1294 (2023). https://doi.org/10.1001/jamaneurol.2023.3599
41 Rosvall, L. *et al.* APOE-related mortality: effect of dementia, cardiovascular disease and gender. *Neurobiology of aging* **30**, 1545-1551 (2009). https://doi.org/10.1016/j.neurobiolaging.2007.12.003
42 McKay, G. J. *et al.* Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. *American journal of epidemiology* **173**, 1357-1364 (2011). https://doi.org/10.1093/aje/kwr015
43 Jorm, A. F. & Jolley, D. The incidence of dementia: a meta-analysis. *Neurology* **51**, 728-733 (1998). https://doi.org/10.1212/wnl.51.3.728
44 Berlau, D. J., Corrada, M. M., Head, E. & Kawas, C. H. APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. *Neurology* **72**, 829-834 (2009). https://doi.org/10.1212/01.wnl.0000343853.00346.a4
45 Shinohara, M. *et al.* APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. *Annals of neurology* **79**, 758-774 (2016). https://doi.org/10.1002/ana.24628
46 Rajan, K. B. *et al.* Racial Differences in the Association Between Apolipoprotein E Risk Alleles and Overall and Total Cardiovascular Mortality Over 18 Years. *Journal American Geriatrics Society* **65**, 2425-2430 (2017). https://doi.org/10.1111/jgs.15059
47 Beydoun, M. A. *et al.* Race, APOE genotypes, and cognitive decline among middle-aged urban adults. *Alzheimers Research & Therapy* **13**, 120 (2021). https://doi.org/10.1186/s13195-021-00855-y
48 Tang, M. X. *et al.* The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. *Jama* **279**, 751-755 (1998). https://doi.org/10.1001/jama.279.10.751
49 Nsor, N. A., Bourassa, K. J., Barnes, L. L. & Brown, C. L. The Effects of APOE Alleles, Cognitive Activities, and Social Activities on Cognitive Decline in African Americans. *The journals of gerontology. Series B, Psychological sciences and social sciences*, gbae172 (2024). https://doi.org/10.1093/geronb/gbae172
50 Shinohara, M. *et al.* APOE2 is associated with longevity independent of Alzheimer's disease. *eLife* **19**, e62199 (2020). https://doi.org/10.7554/eLife.62199
51 Ouellette, N. & Perls, T. Race and ethnicity dynamics in survival to 100 years in the United States. *J Intern Med* **297**, 2-21 (2025). https://doi.org/10.1111/joim.20031

52 Nemes, S., Jonasson, J. M., Genell, A. & Steineck, G. Bias in odds ratios by logistic regression modelling and sample size. *BMC Medical Research Methodology* **9**, 56 (2009). https://doi.org/10.1186/1471-2288-9-56

53 Logue, M. W., Dasgupta, S. & Farrer, L. A. Genetics of Alzheimer's Disease in the African American Population. *J Clin Med* **12**, 5189 (2023). https://doi.org/10.3390/jcm12165189

54 Reitz, C. *et al.* Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4,and the risk of late-onset Alzheimer disease in African Americans. *Jama* **309**, 1483-1492 (2013). https://doi.org/10.1001/jama.2013.2973

55 Rogalski, E. J. *et al.* Enrollment and Scientific Progress of the Multisite SuperAging Research Initiative. *Alzheimer's & Dementia* **19**, e078625 (2023). https://doi.org/10.1002/alz.078625

56 Rogalski, E. J. *et al.* The SuperAging Research Initiative: A multisite consortium focused on identifying factors promoting extraordinary cognitive aging. *Alzheimer's & Dementia* **18**, e066407 (2022). https://doi.org/10.1002/alz.066407

Figure 1. Flow Diagram for Participant Classification of SuperAgers, Cases, and Controls. (A) Flowchart depicting inclusion and exclusion criteria for identifying SuperAgers, AD dementia cases, controls. (B) Flowchart depicting selection order of SuperAgers, cases, and controls. Age range of participants indicated by line segment with arrows on each end. Age of participant classification is indicated by position of shorter, labeled line segments. Closed circles at the end of line segments indicate inclusion of age, such that age range is less-than-or-equal-to or greater-than-or-equal-to the age with which the circle aligns, while open circles indicate exclusion of age, such that age range is less-than or greater-than the age with which the circle aligns. Sequence of selection is indicated by line height, higher lines indicating earlier selection. Abbreviations: ADSP-PHC, Alzheimer's Disease Sequencing Project – Phenotype Harmonization Consortium; AD, Alzheimer's Disease; CN, Cognitively Normal; MEM, Memory; EXF, Executive Functioning; LAN, Language.

Table 1. Participant Characteristics by Cohort.

Participant Demographics	All	ACT	ADNI	BIOCARD	Knight ADRC	NACC	NIA-AD FBS	ROS, MAP, MARS	WRAP
No. participants	18080	2188	825	51	735	11851	645	1462	323
No. observations	78549	13016	3568	455	3314	42004	956	13931	1305
Visits, mean (SD)	4 (4)	6 (3)	4 (3)	9 (3)	5 (4)	4 (3)	1 (1)	10 (6)	4 (2)
Follow-up time, mean (SD), y	5 (5)	10 (6)	3 (3)	13 (4)	4 (5)	3 (4)	2 (3)	9 (6)	9 (5)
Baseline Age, mean (SD), y	72 (10)	73 (6)	74 (7)	53 (9)	74 (8)	72 (10)	74 (12)	77 (8)	53 (6)
NHW Race, No. (%)	15698 (87)	2116 (97)	753 (91)	51 (100)	635 (86)	10149 (86)	605 (94)	1086 (74)	303 (94)
Education, mean (SD), y	15 (3)	15 (3)	16 (3)	17 (2)	15 (3)	16 (3)	14 (3)	16 (4)	16 (3)
Female Sex, No. (%)	11213 (62)	1295 (59)	401 (49)	30 (59)	453 (62)	7319 (62)	406 (63)	1091 (75)	218 (67)
APOE genotype									
ε2/ε2, %	0.4	0.6	0.4	0	0.3	0.4	0.6	0.5	0.3
ε2/ε3, %	8.8	12.5	8.6	13.7	8.7	7.9	5.1	12.1	7.1
ε2/ε4, %	2.6	2.3	2.4	0	2.7	2.6	3.3	2.1	3.4
ε3/ε3, %	47.0	58.8	44.8	62.7	41.9	44.2	37.7	57.9	52.6
ε3/ε4, %	33.5	24.0	33.1	19.6	38.8	35.6	43.1	24.4	32.2
ε4/ε4, %	7.8	1.7	10.7	3.9	7.6	9.4	10.2	2.9	4.3
SuperAgers, No. (%)	1623 (9)	275 (13)	59 (7)	0 (0)	53 (7)	935 (8)	16 (2)	285 (19)	0 (0)
Controls, No. (%)	7628 (42)	1207 (55)	335 (41)	49 (96)	290 (39)	4605 (39)	309 (48)	510 (35)	323 (100)
Cases, No. (%)	8829 (49)	706 (32)	431 (52)	2 (4)	392 (53)	6311 (53)	320 (50)	667 (46)	0 (0)

Abbreviations: NHW, Non-Hispanic White; ACT, Adult Changes in Thought; ADNI, Alzheimer's Disease Neuroimaging Initiative; BIOCARD, Biomarkers of Cognitive Decline Among Normal Individuals; Knight ADRC, Knight Alzheimer's Disease Research Center at Washington University; NACC, National Alzheimer's Coordinating Centers; NIA-AD FBS, National Institute on Aging Alzheimer's Disease Family Based Study; ROS, Religious Orders Study; MAP, Memory and Aging Project; MARS, Minority Aging Research Study; WRAP, Wisconsin Registry for Alzheimer's Prevention.

Table 2. Characteristics of SuperAgers, Cases, and Controls by Race and Age Bin.

A

	SuperAgers	Middle-Aged Controls	Old Controls	Oldest-old Controls	Middle-Aged Cases	Old Cases	Oldest-old Cases
No. participants	1412	1622	3202	1213	1101	3528	3258
No. observations	11528	7067	12308	6980	2692	10858	15434
Visits, mean (SD)	8 (5)	4 (3)	4 (3)	6 (4)	2 (2)	3 (2)	5 (4)
Follow-up time, mean (SD), y	10 (6)	6 (5)	4 (4)	8 (6)	2 (2)	2 (3)	5 (6)
Baseline age, mean (SD), y	77 (7)	57 (5)	70 (4)	79 (7)	59 (5)	73 (4)	83 (6)
Education, mean (SD), y	16 (3)	16 (2)	16 (3)	15 (3)	15 (3)	15 (3)	15 (3)
Female Sex, No. (%)	953 (67)	1119 (69)	1964 (61)	661 (54)	618 (56)	1905 (54)	1989 (61)
APOE-ε2 Frequency, No. (%)	246 (17)	216 (13)	467 (15)	179 (15)	50 (5)	184 (5)	321 (10)
APOE-ε4 Frequency, No. (%)	276 (20)	647 (40)	981 (31)	270 (22)	639 (58)	2495 (71)	1425 (44)

B

	SuperAgers	Middle-Aged Controls	Old Controls	Oldest-old Controls	Middle-Aged Cases	Old Cases	Oldest-old Cases
No. participants	211	296	752	145	85	413	444
No. observations	1830	1024	3106	827	171	1300	2281
Visits, mean (SD)	9 (5)	3 (3)	4 (3)	6 (4)	2 (1)	3 (3)	5 (5)
Follow-up time, mean (SD), y	9 (6)	4 (4)	4 (4)	6 (5)	1 (1)	3 (3)	5 (6)
Baseline age, mean (SD), y	77 (6)	59 (4)	70 (4)	79 (6)	60 (4)	73 (4)	83 (6)
Education, mean (SD), y	15 (3)	15 (3)	15 (3)	13 (3)	14 (3)	14 (4)	13 (4)
Female Sex, No. (%)	177 (84)	222 (75)	564 (75)	115 (79)	58 (68)	283 (69)	331 (75)
APOE-ε2 Frequency, No. (%)	56 (27)	68 (23)	155 (21)	27 (19)	8 (9)	36 (9)	53 (12)
APOE-ε4 Frequency, No. (%)	54 (26)	125 (42)	261 (35)	39 (27)	65 (76)	307 (74)	216 (49)

(A) Non-Hispanic White; (B) Non-Hispanic Black

Table 3. Logistic Regression Model Results Comparing *APOE*-ε2 and -ε4 Allele Frequency among SuperAgers, Cases, and Controls.

A

	APOE-ε2		*APOE*-ε4	
	OR (CI)	P_{FDR}	OR (CI)	P_{FDR}
SuperAgers vs. Middle-Aged Controls	1.38 (1.13, 1.68)	*0.002*	0.37 (0.31, 0.43)	*<0.001*
SuperAgers vs. Old Controls	1.24 (1.05, 1.47)	*0.015*	0.55 (0.47, 0.64)	*<0.001*
SuperAgers vs. Oldest-Old Controls	1.28 (1.03, 1.59)	*0.035*	0.81 (0.67, 0.99)	*0.044*
SuperAgers vs. Middle-Aged Cases	4.55 (3.30, 6.27)	*<0.001*	0.18 (0.15, 0.21)	*<0.001*
SuperAgers vs. Old Cases	4.02 (3.26, 4.96)	*<0.001*	0.09 (0.08, 0.11)	*<0.001*
SuperAgers vs. Oldest-Old Cases	2.03 (1.68, 2.44)	*<0.001*	0.32 (0.27, 0.37)	*<0.001*

B

	APOE-ε2		*APOE*-ε4	
	OR (CI)	P_{FDR}	OR (CI)	P_{FDR}
SuperAgers vs. Middle-Aged Controls	1.19 (0.79, 1.80)	0.423	0.48 (0.33, 0.71)	*0.001*
SuperAgers vs. Old Controls	1.41 (0.99, 2.01)	0.079	0.66 (0.47, 0.94)	*0.035*
SuperAgers vs. Oldest-Old Controls	1.63 (0.93, 2.85)	0.115	1.18 (0.70, 1.98)	0.564
SuperAgers vs. Middle-Aged Cases	3.59 (1.60, 8.06)	*0.005*	0.12 (0.07, 0.22)	*<0.001*
SuperAgers vs. Old Cases	4.56 (2.75, 7.55)	*<0.001*	0.12 (0.08, 0.18)	*<0.001*
SuperAgers vs. Oldest-Old Cases	2.73 (1.75, 4.25)	*<0.001*	0.39 (0.27, 0.57)	*<0.001*

(A) Non-Hispanic White; (B) Non-Hispanic Black. Abbreviations: OR, Odds Ratio; CI, Confidence Interval (95%); P_{FDR}, FDR-corrected P-value.

A



B



Figure 1. Flow Diagram for Participant Classification of SuperAgers, Cases, and Controls.